Fusion Protein Vaccine Based on Ag85B and STEAP1 Induces a Protective Immune Response against Prostate Cancer.

ABSTRACT: (1) Background: There are currently limited treatments for castration-resistant prostate cancer. Immunotherapy involving Sipuleucel-T has increasingly drawn attention for prostate cancer management. BCG plays a vital role in treating bladder cancer, mainly by inducing immune activation, but is rarely used for prostate cancer. (2) Methods: The TCGA database, PCR, and Western blotting were used to analyze the expression of STEAP1 in mouse and human tissues. Then, we constructed a fusion protein vaccine with Mycobacterium tuberculosis Ag85B and three repeated octapeptide epitopes of a six-transmembrane epithelial antigen of the prostate 1 (STEAP1_186-193), Ag85B-3×STEAP1_186-193. The uptake of the fusion protein vaccine by DCs was evaluated by confocal microscopy, a

SUBMITTER: Guo L 

PROVIDER: S-EPMC8310044 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature